•  A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
    Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, Mavroudis D, Georgoulias V.
    Lung Cancer. 2014 Oct;86(1):59-66
  • A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine, as maintenance treatment in advanced non-small cell lung cancer : treatment rationale and protocol dynamics, pdf file to download
    Clin. Lung Cancer, 2013, 14, 461-5
    Georgoulias V., Douillard JY., Khayat D., Manegold C., Rossel R., Rossi A., Menez-Jamet J., Iché M., Kosmatopoulos K., Gridelli C 
  • Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study, pdf file to download
    Ann. Oncol., 2012, 23: 442-9
    Kotsakis A., Vetsika E.K., Christou S., Hatzidaki D., Vardakis N., Aggouraki D., Konsolakis G., Georgoulias V., Christophylakis C., Cordopatis P., Kosmatopoulos K., Mavroudis D.
  •  Immunological response in cancer patients after vaccination with the therapeutic telomerase specific vaccine Vx-001
    Cancer Immunol. Immunother., 2012, 61: 157-68, pdf file to download
    Vetsika E.K, Konsolakis G., Aggouraki D., Kotsakis A., Papadimitraki E., Christou S., Menez-Jamet J., Kosmatopoulos K., Georgoulias V., Mavroudis D.
  •  Development of optimized cryptic peptides in immunotherapy
    iDrug, 2009, 12, 92-102, pdf file to download
    Menez-Jamet J and Kosmatopoulos KEBR Summer 2007 Vaxon
  • Improving Tumour Immunity
    European Biotech Review, 2007 Summer, 56-58, pdf file to download
    Abastado JP and Kosmatopoulos K
  • Vaccination of Patients With Advanced Non–Small-Cell Lung Cancer With an Optimized Cryptic Human Telomerase Reverse Transcriptase Peptide.
    Journal of Clinical Oncology, 2007 July, 25 (19), 2729-34; pdf file to download
    Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki, D Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V, and Mavroudis D
  • A Polyepitope DNA Vaccine Targeted to Her-2/ErbB-2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor Challenge
    Cancer Res., 2007 July 15, 67 (14), 7028-36, pdf file to download
    Scardino A, Alimandi M, Correale P, Smith SG, Bei R, Firat H, Grazia Cusi M,  Faure O, Graf-Dubois S, Cencioni G, Marrocco J, Chouaib S, Lemonnier FA,  Jackson AM and Kosmatopoulos K
  • STEAP, a prostate tumor antigen, is a target of human CD8(+) T cells.
    Cancer Immunol Immunother. 2006 Dec;55(12):1515-23, pdf file to download
    Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA, Kosmatopoulos K.
  • A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies.
    Oncology. 2006;70(4):306-14., 2006 Oct 12, pdf file to download
    Mavroudis D, Bolonakis I, Cornet S, Myllaki G, Kanellou P, Kotsakis A, Galanis A, Nikoloudi I, Spyropoulou M, Menez J, Miconnet I, Niniraki M, Cordopatis P, Kosmatopoulos K, Georgoulias V
  • Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity.
    Vaccine. 2006 Mar 15;24(12):2102-9, PDF file to download
    Cornet S, Miconnet I, Menez J, Lemonnier F, Kosmatopoulos K.  
  • CpG oligodeoxynucleotides activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT derived modified cryptic MHC class I-restricted epitope.
    Vaccine. 2006 Mar 10;24(11):1880-8, PDF file to download
    Cornet S, Menez-Jamet J, Lemonnier F, Kosmatopoulos K, Miconnet I.
  • pH-triggered microparticles for peptide vaccination.
    J Immunol. 2004 Aug 15;173(4):2578-85, PDF file to download
    Haining WN, Anderson DG, Little SR, von Bergwelt-Baildon MS, Cardoso AA, Alves P, Kosmatopoulos K, Nadler LM, Langer R, Kohane DS.
  • High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy
    J Clin Invest. 2004 Feb;113(3):425-33. PDF file to download
    Gross DA,  Graff-Dubois S, Opolon P, Cornet, S Alves P, Faure O, Guillaume P, Chouaib S, Lemonnier, FA, Miconnet I, Vonderheide RH, and Kosmatopoulos K.
  • EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes
    Cancer Res. 2003 Dec 1;63(23):8476-80. PDF file to download
    Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K.
  • Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
    J Immunol. 2002 Jul 1;169(1):575-80. PDF file to download
    Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K.
  • HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy.
    J Immunol. 2002 Jun 1;168(11):5900-6. PDF file to download
    Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K.
  • Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors.
    Eur J Immunol. 2001 Nov;31(11):3261-70. PDF file to download
    Scardino A, Alves P, Gross DA, Tourdot S, Graff-Dubois S, Angevin E, Firat H, Chouaib S, Lemonnier F, Nadler LM, Cardoso AA, Kosmatopoulos K.
  • A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes.
    Eur J Immunol. 2000 Dec;30(12):3411-21. PDF file to download
    Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA, Kosmatopoulos K.